Evidence map›Paper›PMID 42292386›Full record

ArticleFrontiers in immunology2026

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study.

Huilin Lu, Tao Xu, Jing Li, Bufu Tang, Yulan Zeng, Xinghai Li, Jiangping Cun, Xiangwen Xia, Jihong Hu, Xuancheng Xie and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huilin Lu *Department of Interventional Therapy, Xinxiang Central Hospital / the Fourth Clinical College of Xinxiang Medical University, Xinxiang, Henan, China.
Tao Xu *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jing Li *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Bufu TangDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yulan ZengCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xinghai LiDepartment of Minimally Invasive Intervention, Ganzhou People's Hospital, Ganzhou, China.
Jiangping CunDepartment of Radiology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Xiangwen XiaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jihong HuDepartment of Interventional Radiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Xuancheng XieDepartment of Radiology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital, Kunming, China.
Hongjie FanDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Icaritin, a prenylated flavonoid extracted from Methods: This multicenter retrospective cohort study, conducted from October 2022 to June 2025, included 288 patients with HCC and MVI from five tertiary hospitals. Patients were assigned to either the TACE plus Icaritin group (n = 144) or the TACE monotherapy group (n = 144). Tumor response was evaluated by mRECIST on contrast-enhanced CT/MRI. Overall survival and progression-free survival were estimated using Kaplan Meier curves and compared by log-rank test; prognostic factors were identified via Cox regression. Results: The Icaritin-TACE group showed significantly better outcomes, with longer median OS (16.3 vs. 13.3 months; P = 0.020) and PFS (8.5 vs. 7.6 months; P = 0.006) than the TACE monotherapy group. The disease control rate (DCR) was also higher in the Icaritin-TACE group (84.0% vs. 72.2%; P = 0.015). Multivariate Cox regression analysis identified ECOG performance status, alpha-fetoprotein (AFP) levels, number of lesions, and maximum lesion diameter as independent predictors of OS, while lesion count was independently associated with PFS. The overall incidence of any grade adverse events was similar between groups. Conclusion: Icaritin combined with TACE improves OS, PFS, and DCR compared to TACE alone in patients with MVI-associated HCC.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticFlavonoidsLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesTreatment OutcomeFlavonoidsicaritinhepatocellular carcinomamacrovascular invasionsurvival outcomestransarterial chemoembolizationtumor response

Identifiers

PMID42292386
PMCPMC13260649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.